Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRXBiotechnology
+$0.07 today
- Market cap
- $417.57M
- Beta
- 1.48
- P/E (TTM)
- -8.5
- EPS (TTM)
- -$0.74
Volume 1.21M
Average 0.22M
EPRX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures grows, but more slowly than its trailing trend
Q1 FY2026 capital expenditures of $322.43K (cash outflow) rose 90.7% year over year, behind the +188.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 64.3% from the prior quarter. Over 3 fiscal years it compounded at +36.5% a year.
Context
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +90.7% toward the trailing-twelve-month pace of +188.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
Mixed currencies · from the cash flow
- Latest · FY2025
- (598.77K) USD
- Year-over-year change
- -474.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (598.77K) | -474.5% |
| FY2024 | 2024-12-31 | (104.23K) | -88.7% |
| FY2023 | 2023-12-31 | (55.25K) | — |
| FY2022 | 2022-12-31 | (235.55K) | +31.0% |
| FY2021 | 2021-12-31 | (341.28K) | — |
Capital Expenditures vs competitors
How EPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +188.5% is the highest of 8, against a peer median of -8.7%.
- Over three fiscal years its annual growth of +36.5% compares with a peer median of -7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.46M USD | +8.2% | +114.9% | 44.6% | |
| LTM Mar 2026 | $4.41M USD | -53.9% | +65.6% | 248.2% | |
| LTM Mar 2026 | $1.57M USD | -7.4% | -18.1% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $728.23K USD | +188.5% | +36.5% | — |
| LTM Mar 2026 | $561K USD | +42.7% | -6.1% | 1.7% | |
| FY2025 | €237.26K EUR | -28.8% | -24.9% | 5.3% | |
| LTM Mar 2026 | $95K USD | -8.7% | — | — | |
| LTM Mar 2026 | $50K USD | -53.3% | -7.8% | — | |
| LTM Mar 2026 | $8 USD | — | — | — | |
| LTM Sep 2026 | $0 USD | — | — | — | |
| Peer median (excluding EPRX) | — | -8.7% | -7.0% | 25.0% | |
Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (18.18M) | (18.99M) | (21.81M) | (25.74M) | (39.22M) |
| Depreciation & Amortization | 88.17K | 147.89K | 117.1K | 171.72K | 241.68K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 1.43M | 1.06M | 3.22M | 0 |
| Change in Working Capital | (167.16K) | 1.51M | 4.03M | (6.76M) | (725.6K) |
| Accounts Receivables | 150.92K | 230.48K | (78.09K) | (101.39K) | (438.64K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 1.32M | 435.12K | (714.88K) | 2.4M |
| Other Working Capital | (318.07K) | (39.96K) | 3.67M | (5.95M) | (2.69M) |
| Other Non-Cash Items | 6.68M | 1.5M | 977.18K | (880.5K) | 10.68M |
| Operating Cash Flow | (11.58M) | (14.4M) | (15.62M) | (29.99M) | (29.03M) |
| Capital Expenditures | (341.28K) | (235.55K) | (55.25K) | (104.23K) | (598.77K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | (3.27M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 13.34M | 0 | 0 | 0 |
| Other Investing Activities | (3.97M) | 242 | 0 | 29.07K | 0 |
| Investing Cash Flow | (11.42M) | 9.83M | (55.25K) | (75.16K) | (598.77K) |
| Debt Repayment | 9.62M | (142.27K) | (59.81K) | (9.14M) | 0 |
| Common Stock Issued | 29.91M | 10.64M | 11.96M | 54.56M | 77.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (69.33K) | 306.77K | 3.97M | 363.06K | 0 |
| Financing Cash Flow | 39.46M | 10.8M | 15.87M | 45.78M | 77.33M |
| Effect of Forex Changes | (63.69K) | (507.4K) | 618.45K | (1.96M) | (403.1K) |
| Net Change in Cash | 16.4M | 5.73M | 811.93K | 13.76M | 47.3M |
| Free Cash Flow | (11.92M) | (14.63M) | (15.68M) | (30.1M) | (29.63M) |
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
Intrinsic Alpha fair value
Locked
Current Price
$6.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.